A genetic mutation passed from mother to children in families affected by schizophrenia has now been shown to completely ...

WASHINGTON — Federal health officials are unilaterally reducing the number of recommended pediatric immunizations in response ...

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), ...

For most of their lives, the two women have stayed tucked away indoors, sidelined by a rare blood disorder that makes the ...

G-protein coupled receptors (GPCRs) are proteins triggered by ligands (protein-binding chemicals) from outside cells to ...

The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...

A new chemical method that could speed up the creation of medicines, materials and products people rely on every day has been developed by University of Hawaiʻi at Mānoa Department of Chemistry ...

President Donald Trump says Americans could soon pay far less for GLP-1 medications used for diabetes, obesity, and heart disease. He announced that his administration has secured a deal to bring ...

Pirates pitcher Paul Skenes is a candidate to bring home another MLB award this month. / Charles LeClaire-Imagn Images With a thrilling 2025 World Series in the books, it’s time to look ahead to MLB ...

A Northwestern team transformed a common chemotherapy drug into a powerful, targeted cancer therapy using spherical nucleic acids. The redesign dramatically boosted drug absorption and cancer-killing ...

Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...